Brian Druker
American physician-scientist / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Brian J. Druker?
Summarize this article for a 10 year old
Brian J. Druker (born April 30, 1955)[1] is a physician-scientist at Oregon Health & Science University (OHSU), in Portland, Oregon. He is the director of OHSU's Knight Cancer Institute,[2][3] JELD-WEN Chair of Leukemia Research, Associate Dean for Oncology in the OHSU School of Medicine, and professor of medicine.[4]
Brian J. Druker | |
---|---|
Born | (1955-04-30) April 30, 1955 (age 69) St. Paul, Minnesota |
Nationality | American |
Alma mater | University of California, San Diego, Washington University School of Medicine |
Known for | Gleevec |
Awards | Novartis-Drew Award (2002) Robert Koch Prize (2005) Keio Medical Science Prize (2007) Meyenburg Award (2009) Lasker Clinical Award (2009) Japan Prize (2012) Dickson Prize (2012) Albany Medical Center Prize (2013) Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences (2013-14) Tang Prize (2018) The Sjöberg Prize (2019) |
Scientific career | |
Fields | Oncology |
Institutions | Howard Hughes Medical Institute, Oregon Health & Science University |
Druker helped develop imatinib (Gleevec), the first medication that specifically targets cancer cells, for the treatment of chronic myeloid leukemia (CML).[5][6][7] In 2001, Gleevec gained FDA approval in record time[8] and landed on the cover of Time magazine.[9] Druker’s work launched the era of precision cancer medicine, setting the stage for future discoveries in the quest to end cancer.[10]
He is the recipient of the 2009 Lasker-DeBakey Clinical Medical Research Award,[11] the 2012 Japan Prize in Healthcare and Medical Technology,[12] the 2013 Albany Medical Center Prize in Medicine and Biomedical Research,[13] and the 2019 Sjöberg Prize,[14] among others. He has been called "Oregon's best-known scientist".[15]